Barcelona-based pharmaceutical company Grifols announced Thursday that its annual earnings reached 402 million euros ($473.96 million) in 2025, representing more than a twofold increase compared to the prior year’s results, fueled by company revenues that climbed to 7.5 billion euros.
The Spanish drugmaker’s revenue figures showed a 7% year-over-year increase, while financial experts surveyed by LSEG had anticipated profits of 427 million euros alongside revenues matching the actual 7.5 billion euro result.
The company’s adjusted EBITDA—earnings before interest, taxes, depreciation and amortization—climbed to 1.8 billion euros, meeting analyst projections for the reporting period.
Despite these positive financial results, Grifols has experienced significant market turbulence, with its stock value declining approximately 25% since the beginning of 2024. This downturn followed the publication of several critical reports by short-selling firm Gotham City Research, which alleged that the pharmaceutical company had inflated its earnings figures while downplaying its debt obligations—claims that Grifols has firmly rejected and challenged through legal action against the investment fund.
